Astraveus opens path to accessible cell therapies with first ever end-to-end microfluidic CAR-T production
Paris, France, 9 January 2025 – Astraveus SAS (“Astraveus” or the “Company”), the Benchtop Cell Factory company, today announces the first ever successful end-to-end production of CAR-T cells within a microfluidic benchtop system. Using its fully automated Lakhesys Benchtop Cell FactoryTM, Astraveus has been able to demonstrate the potential of its unique microfluidic cell therapy processing approach, which has the ability to decrease manufacturing costs and increase throughput by an order of magnitude.
